Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 589 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FDG Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction

NCT04417998
View directory record Official record
Conditions
Brain Imaging, Whole Body Imaging
Interventions
18F-FDG, 18F-AV1451, Siemens E7 Reconstruction Tool
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 18, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

NCT06244004
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Antiandrogen Therapy, Bone Scan, Computed Tomography, Cytotoxic Chemotherapy, FDG-Positron Emission Tomography, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 9:22 AM EDT
Completed No phase listed Observational

Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC)

NCT01146366
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Jennifer Bell
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 18, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

NCT02167256
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AZD0530 100mg daily, AZD0530 125mg daily, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
55 Years to 85 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
21
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 18, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation

NCT00313027
View directory record Official record
Conditions
Head and Neck Cancer, Carcinoma, Squamous Cell, Head and Neck Cancers
Interventions
PET scan
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 18, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer

NCT01190527
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
FDG-PET
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 18, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Results available

Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules

NCT00906503
View directory record Official record
Conditions
Pulmonary Nodule
Interventions
dexamethasone, PET/Computed Tomography (CT), fludeoxyglucose (18F)
Drug · Procedure · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 18, 2026, 9:22 AM EDT
Completed Early Phase 1 Interventional

Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma

NCT04114370
View directory record Official record
Conditions
Glioma
Interventions
18F-fluciclovine
Drug
Lead sponsor
James Mountz
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 18, 2026, 9:22 AM EDT
Terminated Not applicable Interventional Results available

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

NCT02149173
View directory record Official record
Conditions
Estrogen Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 18, 2026, 9:22 AM EDT
Completed Early Phase 1 Interventional

Brain Inflammation and Function in Alcoholism

NCT02233868
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
connectivity, neuroinflammation, neurofunction
Other · Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
30 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 9:22 AM EDT
Terminated Not applicable Interventional

Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection

NCT05513027
View directory record Official record
Conditions
Cancer
Interventions
Augmented Whole-body Scanning via Magnifying PET, PET/CT
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 18, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer

NCT01826227
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube, Primary Peritoneal
Interventions
Positron Emission Tomography, 18F-Fluoro-2-deoxy-D-lucose, Cytoreductive surgery
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 18, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

NCT00381797
View directory record Official record
Conditions
Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma
Interventions
Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride
Biological · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 18, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Results available

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00809341
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Ifosfamide, Carboplatin, Etoposide, High-dose cyclophosphamide, PET scan
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 18, 2026, 9:22 AM EDT
Not yet recruiting Phase 1 Interventional

Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

NCT07691450
View directory record Official record
Conditions
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type, Recurrent Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma, Recurrent Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular Helper T-Cell Lymphoma, Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Refractory Follicular Helper T-Cell Lymphoma, Follicular-Type, Refractory Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma, Refractory Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions
Azacitidine, Belinostat, Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Pralatrexate, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 18, 2026, 9:22 AM EDT
Terminated Not applicable Interventional Results available

FDG-PET in Advanced Melanoma

NCT02236546
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
[18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography, computed tomography
Diagnostic Test · Other · Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 18, 2026, 9:22 AM EDT
Not listed Phase 2 Interventional

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

NCT00083083
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 18, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma

NCT00802880
View directory record Official record
Conditions
Sarcoma
Interventions
Dacarbazine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 18, 2026, 9:22 AM EDT
Terminated Not applicable Interventional Results available

Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma

NCT00060008
View directory record Official record
Conditions
Neurofibromatosis Type 1, Precancerous Condition
Interventions
fludeoxyglucose F 18, gadopentetate dimeglumine
Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 18, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

NCT03173924
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer, Prostatic Cancer, Prostate Neoplasms
Interventions
18F-NaF, 18F-DCFPyL, 18F-FDG
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 9:22 AM EDT
Active, not recruiting Phase 3 Interventional

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

NCT03811015
View directory record Official record
Conditions
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Echocardiography Test, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Nivolumab, Patient Observation, Positron Emission Tomography
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
727
States / cities
Fairhope, Alabama • Mobile, Alabama • Anchorage, Alaska + 462 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

NCT03789240
View directory record Official record
Conditions
Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL
Interventions
Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy, CT Scans, 18F-FDG-PET/CT Scan15, Electrocardigram
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 18, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

NCT03206060
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors, Neuroendocrine Neoplasms
Interventions
Lu-177-DOTATATE, Ga-68-DOTATATE
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 9:22 AM EDT
Recruiting No phase listed Observational

Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)

NCT07604220
View directory record Official record
Conditions
Cardiac Sarcoidosis, Sarcoidosis of the Heart, Sarcoidosis With Myocarditis, Sarcoidosis, Cardiac
Interventions
Exosome Analysis
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 18, 2026, 9:22 AM EDT